Application of anti-CD20 monoclonal antibodies in the treatment of lymphoproliferative diseases (original) (raw)
CD20 as a target for therapy
U. Demkow, M. Winiarska
2007
View PDFchevron_right
Anti-CD20 monoclonal antibodies: historical and future perspectives
Mark Cragg
Haematologica, 2010
View PDFchevron_right
Monoclonal anti-CD20 antibodies: Mechanisms of action and monitoring of biological effects
Yves Renaudineau
Joint Bone Spine, 2009
View PDFchevron_right
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
Mark Cragg
Blood, 2004
View PDFchevron_right
Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells
Lukas Frenzel
British Journal of Haematology, 2011
View PDFchevron_right
Monoclonal antibodies targeting CD20
Edmund Rossi
mAbs, 2013
View PDFchevron_right
CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies
Mark Cragg
Seminars in Hematology, 2010
View PDFchevron_right
Characterisation of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin's lymphomas
Mark Cragg
2004
View PDFchevron_right
Novel CD20 monoclonal antibodies for lymphoma therapy
Nikhil Mukhi
Journal of Hematology & Oncology, 2012
View PDFchevron_right
A new approach to comparing anti-CD20 antibodies: importance of the lipid rafts in their lytic efficiency
Anne Bordron
OncoTargets and Therapy, 2010
View PDFchevron_right
Differential Action of Anti-CD20 Monoclonal Antibodies: Role in Induction of Cell Death
damodar Gupta
Journal of Cancer Science & Therapy, 2018
View PDFchevron_right
Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope
Kiichi Fukui
Cancer Science, 2000
View PDFchevron_right
Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas
Julia Rincon
Cancer Treatment Reviews, 2015
View PDFchevron_right
Biochemical and biophysical characterization of purified native CD20 alone and in complex with rituximab and obinutuzumab
Philippe Ringler
Scientific Reports, 2019
View PDFchevron_right
Antibody against CD20 in patients with B cell malignancy
Glenn Pilkington
Leukemia Research, 2001
View PDFchevron_right
Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders
Jorge Castillo
Expert Opinion on Investigational Drugs, 2009
View PDFchevron_right
New anti-CD20 monoclonal antibodies: who is the best?
anne-laure gagez
2014
View PDFchevron_right
Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab
G. Dastoli
Critical Reviews in Oncology/Hematology, 2001
View PDFchevron_right
Immunotherapy with anti-CD20 compounds
Christoph von Schilling
Seminars in Cancer Biology, 2003
View PDFchevron_right
Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response
damodar Gupta
Journal of Cancer Science & Therapy, 2015
View PDFchevron_right
Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
Mark Cragg
Frontiers in immunology, 2017
View PDFchevron_right
The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden
Frank Beurskens
Haematologica, 2011
View PDFchevron_right
Production and Characterization of New Anti-Human CD20 Monoclonal Antibody
Kazem Ahmadi
Iranian journal of allergy, asthma, and immunology, 2015
View PDFchevron_right
Blockade of CD200 in the Presence or Absence of Antibody Effector Function: Implications for Anti-CD200 Therapy
R. Cofiell
The Journal of Immunology, 2008
View PDFchevron_right
[177Lu]DOTA-anti-CD20: Labeling and pre-clinical studies
Ana Robles
Applied Radiation and Isotopes, 2011
View PDFchevron_right
In vitro characterization of 177 Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study
Helmut Maecke
European Journal of Nuclear Medicine and Molecular Imaging, 2009
View PDFchevron_right